Dosing Afrezza: It’s Not that Complicated

Afrezza inhaled insulin offers a unique alternative to subcutaneous insulin delivery, providing a rapid onset to effectively manage postprandial glucose spikes with a short duration of action that minimizes delayed postprandial hypoglycemia. Although Afrezza has been commercially available for more than a decade, its adoption has been limited by lack of clinician awareness, confusion about dosing, and skepticism about its efficacy and safety. This article presents our perspectives on Afrezza regarding dosing and titration strategies, patient selection and education, and other practical considerations.

Authors

Institutions

Publication Details

Journal
Diabetes Technology & Therapeutics
Published
2026-02-01
DOI
https://doi.org/10.1177/15209156251403580
Citations
1
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
30.73
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dosing Afrezza: It’s Not that Complicated

Irl B. Hirsch, Christopher G. Parkin, Steve V. Edelman, Thomas C. Blevins
1 citations
Diabetes Technology & Therapeutics
Diabetes Management and Research
30.73
article

Dosing Afrezza: It’s Not that Complicated

Irl B. Hirsch, Christopher G. Parkin, Steve V. Edelman, Thomas C. Blevins
article en
1 citations

Abstract

Afrezza inhaled insulin offers a unique alternative to subcutaneous insulin delivery, providing a rapid onset to effectively manage postprandial glucose spikes with a short duration of action that minimizes delayed postprandial hypoglycemia. Although Afrezza has been commercially available for more than a decade, its adoption has been limited by lack of clinician awareness, confusion about dosing, and skepticism about its efficacy and safety. This article presents our perspectives on Afrezza regarding dosing and titration strategies, patient selection and education, and other practical considerations.

Diabetes Technology & TherapeuticsVol. 28(1_suppl)
Sierra Nevada Corporation (United States) (US), University of Washington Medical Center (US), University of California San Diego (US), Texas Diabetes & Endocrinology (US)
Openalex Percentile: Top 1%
Diabetes Management and Research
30.73
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.